FCGR2B and cancer: CONCLUSIONS: This study establishes a glycosylation-integrated CHO display platform for precision FcγRIIIa-targeted Fc engineering, generating modular effector domains with broad allotype compatibility, minimal FcγRIIb binding, and robust therapeutic potential in cancer immunotherapy.